TMCnet News
Ewing Sarcoma - Pipeline Review, H2 2017 - Research and MarketsThe "Ewing Sarcoma - Pipeline Review, H2 2017" report has been added to Research and Markets' offering. Ewing Sarcoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ewing Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Ewing Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 13, 6, 20 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 2 and 2 molecules, respectively.
Key Topics Covered:
For more information about this report visit https://www.researchandmarkets.com/research/6cgjg7/ewing_sarcoma?w=4 View source version on businesswire.com: http://www.businesswire.com/news/home/20171207005913/en/ |